CD274 and cancer: The study of the PD-1/PD-L1 axis in tumors, which are effectively able to evade the guard of the immune system, has led to the possibility of improving cancer treatment using immunotherapeutic agents such as anti-PD-1/PD-L1 monoclonal antibodies, commonly called immune checkpoint inhibitors (ICIs) [15].